Clene Inc. (CLNN) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-05

Key Insights

Director Ugwumba Chidozie sold 78,679 shares across two transactions (5,795 shares on 05/01/2026 at $6.01 and 72,884 shares on 05/04/2026 at $6.80), reducing indirect beneficial ownership from 271,774 to 198,890 shares held through SymBiosis II, LLC.
Both sales occurred at relatively modest price points ($6.01-$6.80), suggesting the director executed sales during a period of limited stock appreciation, which could indicate lack of confidence in near-term price catalysts.
The sales represent a meaningful 29% reduction in the director's beneficial ownership stake within a 4-day period, though sales remain entirely indirect through a related entity rather than direct personal holdings.
All transactions were properly disclosed through indirect ownership structures, with no derivative securities activities reported, indicating routine portfolio management by an insider with director-level responsibilities.

Want the newest filings?

This analysis covers the filing from 2026-05-05. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-30

Director Ugwumba Chidozie executed three consecutive sales of common stock over a 2-day period (04/28-04/30/2026), totaling 19,497 shares, reducing beneficial ownership from approximately 295,475 to 277,569 shares.
All sales were conducted at relatively low price points ($5.63-$6.08 range), suggesting the insider may be taking profits or rebalancing holdings during a period of modest stock valuation.
The shares were sold indirectly through SymBiosis II, LLC, indicating a structured ownership arrangement typical of insider holdings, with no derivative securities activity reported.

Filed: 2026-04-22

Director Ugwumba Chidozie executed two substantial sales totaling 65,663 shares of CLNN common stock over two consecutive trading days (04/20-04/21/2026) at prices ranging from $6.12-$6.14, reducing his indirect beneficial ownership by approximately 18%.
All shares were sold indirectly through SymBiosis II, LLC, indicating a structured divestment rather than opportunistic selling, which may suggest strategic portfolio rebalancing or liquidity needs by this significant insider.
The timing of consecutive day sales at relatively stable pricing ($6.12-$6.14) during a coordinated two-day window raises questions about the motivation behind the substantial insider liquidation by a director-level stakeholder.

Filed: 2026-04-06

Chidozie Ugwumba, a director of Clene Inc. (CLNN), sold 24,925 shares of the company's common stock on April 2, 2026 at a price of $4.81 per share.
Following the reported transaction, Ugwumba now beneficially owns 401,891 shares of Clene Inc. indirectly through SymBiosis II, LLC.
The sale of shares by a director could signal a potential change in sentiment or outlook for the company, which investors should monitor closely.

Filed: 2026-04-01

Chidozie Ugwumba, a 10% owner of Clene Inc. (CLNN), sold 4,278 shares of common stock on April 1, 2026 at an average price of $4.97 per share.
This transaction reduced Ugwumba's beneficial ownership of Clene Inc. common stock to 426,816 shares, which he holds indirectly through SymBiosis II, LLC.
Insider selling can sometimes signal a lack of confidence in the company's future prospects, so this transaction may be viewed as a potentially negative signal by investors.

Filed: 2026-03-31

Chidozie Ugwumba, a director of Clene Inc. (CLNN), has sold a significant portion of his indirect holdings in the company, reducing his stake from 514,621 shares to 431,094 shares over the past three trading days.
The sales were made at prices ranging from $4.75 to $5.10 per share, suggesting Ugwumba may have been taking profits or rebalancing his portfolio.
Investors should monitor insider trading activity and assess whether Ugwumba's sales are a signal of his confidence in the company's future prospects.

Filed: 2026-03-26

Chidozie Ugwumba, a director of Clene Inc. (CLNN), has been selling a significant amount of the company's common stock over the past three trading days, disposing of over 17,900 shares in total.
The sales were executed at prices ranging from $5.40 to $5.78 per share, suggesting Ugwumba may have concerns about the company's current valuation or near-term prospects.
Investors should monitor whether this insider selling activity continues, as it could signal a potential lack of confidence in the company's outlook from a key director.

Filed: 2026-02-20

Arjun Desai, a director of Clene Inc., has been granted a stock option for 3,168 shares at an exercise price of $4.73 per share, vesting immediately on the grant date of February 19, 2026.
The option grant suggests that Desai, an insider, has confidence in the company's future prospects and is aligning his interests with shareholders.
The immediate vesting of the option indicates that the company is incentivizing Desai to continue providing strategic guidance and oversight as a member of the Board of Directors.

Filed: 2026-02-20

Vallerie McLaughlin, a director of Clene Inc., was granted a stock option for 3,030 shares of common stock on February 19, 2026 under the company's Amended 2020 Stock Plan, with an exercise price of $4.73 per share.
The option vests immediately upon grant, indicating potential alignment between the director's interests and those of shareholders.
Insider transactions, such as this stock option grant, can provide insights into management's confidence in the company's future prospects.

Filed: 2026-02-20

Reed N. Wilcox, a director of Clene Inc., was granted a stock option to purchase 3,306 shares of the company's common stock at an exercise price of $4.73 per share on February 19, 2026.
The option vests immediately upon grant, indicating potential confidence in the company's future performance by an insider.
This transaction is part of the company's Amended 2020 Stock Plan, which suggests an ongoing equity incentive program to align management and director interests with shareholders.

Filed: 2026-02-20

Alison Mosca, a director of Clene Inc. (CLNN), was granted a stock option for 4,201 shares at an exercise price of $4.73 per share, vesting immediately.
The option grant suggests Mosca's continued commitment and alignment with Clene Inc.'s long-term interests as a director.
The timing and nature of the option grant do not indicate any significant changes in Mosca's ownership or Clene Inc.'s governance.

Filed: 2026-02-20

The reporting person, David J. Matlin, acquired 5,372 stock options of Clene Inc. at an exercise price of $4.73 per share, vesting immediately.
This stock option grant indicates potential confidence from the director in the company's future prospects.
Insider buying can signal management's belief in the company's growth potential, which may be positive for investors.

Filed: 2026-02-20

Shalom Jacobovitz, a director of Clene Inc., was granted a stock option for 4,098 shares of the company's common stock at an exercise price of $4.73 per share. The option vests immediately upon grant, indicating the company's confidence in Jacobovitz's leadership.
The timing of this stock option grant, occurring on February 19, 2026, suggests the company may be positioning itself for future growth or strategic initiatives, given the director-level involvement.
The immediate vesting of the option could signal Clene Inc.'s desire to incentivize and retain Jacobovitz, a key member of the board, potentially aligning his interests with those of the shareholders.

Filed: 2026-02-20

Insider Jonathan Gay acquired 3,271 stock options in Clene Inc. (CLNN) on February 19, 2026, exercisable at $4.73 per share. The options vested immediately upon grant.
The acquisition of these options suggests that the insider is bullish on the company's future performance and may indicate confidence in the stock's potential upside.
Insider transactions can provide valuable insights into management's views on the company's prospects, which investors may find informative when evaluating the stock.

Other reports for Clene Inc.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.